Int Arch Allergy Immunol:永久过敏性鼻炎中曲安奈德与丙酸氟替卡松治疗对比研究

2019-04-03 AlexYang MedSci原创

鼻内喷雾被推荐作为过敏性鼻炎(AR)的一种靶向治疗方法。曲安奈德是一种鼻腔皮质类固醇制剂,在不同的国家均应用于季节性和永久性AR(PAR)的治疗。最近,有研究人员确定了曲安奈德在治疗PAR中的效果,并评估了曲安奈德相对于丙酸氟替卡松的非劣效性。研究是一个随机、双盲、具有平行组、多中心、前瞻性和非劣效性及阶段3临床试验,总共包括了260名永久PAR患者。他们随机的进行为期4周的曲安奈德相和丙酸氟替卡

鼻内喷雾被推荐作为过敏性鼻炎(AR)的一种靶向治疗方法。曲安奈德是一种鼻腔皮质类固醇制剂,在不同的国家均应用于季节性和永久性AR(PAR)的治疗。最近,有研究人员确定了曲安奈德在治疗PAR中的效果,并评估了曲安奈德相对于丙酸氟替卡松的非劣效性。

研究是一个随机、双盲、具有平行组、多中心、前瞻性和非劣效性及阶段3临床试验,总共包括了260名永久PAR患者。他们随机的进行为期4周的曲安奈德相和丙酸氟替卡松鼻喷雾治疗。症状的控制通过反映鼻腔症状总分(rTNSS)来进行评估。研究发现,在2个组中,rTNSS平均值从基线到研究结束一直在下降。2个小组中rTNSS从基线变化的平均差(酸曲安奈德-氟替卡松)为-0.2(95%置信区间-0.89-0.54),置信上线为0.54,该值要比非劣效性边缘值0.8更低。另外,曲安奈德具有良好的耐受性,在副作用事件上与丙酸氟替卡松没有差异。

最后,研究人员指出,曲安奈德与丙酸氟替卡松在成年人的AR治疗上是非劣效性的。2种治疗方法均减少rTNSS值和表现出了良好的安全性。

原始出处:

Karaulov AV, Vylegzhanina T, Ovchinnikov A et al. Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial. Int Arch Allergy Immunol. 15 Mar 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047095, encodeId=bd18204e09510, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 12 19:55:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706081, encodeId=f5941e0608143, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Mon Aug 05 17:55:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038435, encodeId=0645203843593, content=<a href='/topic/show?id=39f9209549e' target=_blank style='color:#2F92EE;'>#丙酸氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20954, encryptionId=39f9209549e, topicName=丙酸氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Jan 20 00:55:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329223, encodeId=c61e13292239e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568824, encodeId=10fe15688242c, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047095, encodeId=bd18204e09510, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 12 19:55:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706081, encodeId=f5941e0608143, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Mon Aug 05 17:55:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038435, encodeId=0645203843593, content=<a href='/topic/show?id=39f9209549e' target=_blank style='color:#2F92EE;'>#丙酸氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20954, encryptionId=39f9209549e, topicName=丙酸氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Jan 20 00:55:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329223, encodeId=c61e13292239e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568824, encodeId=10fe15688242c, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2019-08-05 gujh
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047095, encodeId=bd18204e09510, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 12 19:55:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706081, encodeId=f5941e0608143, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Mon Aug 05 17:55:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038435, encodeId=0645203843593, content=<a href='/topic/show?id=39f9209549e' target=_blank style='color:#2F92EE;'>#丙酸氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20954, encryptionId=39f9209549e, topicName=丙酸氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Jan 20 00:55:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329223, encodeId=c61e13292239e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568824, encodeId=10fe15688242c, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047095, encodeId=bd18204e09510, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 12 19:55:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706081, encodeId=f5941e0608143, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Mon Aug 05 17:55:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038435, encodeId=0645203843593, content=<a href='/topic/show?id=39f9209549e' target=_blank style='color:#2F92EE;'>#丙酸氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20954, encryptionId=39f9209549e, topicName=丙酸氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Jan 20 00:55:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329223, encodeId=c61e13292239e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568824, encodeId=10fe15688242c, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2019-04-05 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2047095, encodeId=bd18204e09510, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Aug 12 19:55:00 CST 2019, time=2019-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706081, encodeId=f5941e0608143, content=<a href='/topic/show?id=9ffc6023393' target=_blank style='color:#2F92EE;'>#曲安奈德#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60233, encryptionId=9ffc6023393, topicName=曲安奈德)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6a531161088, createdName=gujh, createdTime=Mon Aug 05 17:55:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038435, encodeId=0645203843593, content=<a href='/topic/show?id=39f9209549e' target=_blank style='color:#2F92EE;'>#丙酸氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20954, encryptionId=39f9209549e, topicName=丙酸氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Mon Jan 20 00:55:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329223, encodeId=c61e13292239e, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568824, encodeId=10fe15688242c, content=<a href='/topic/show?id=dc1d6392e50' target=_blank style='color:#2F92EE;'>#氟替卡松#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63927, encryptionId=dc1d6392e50, topicName=氟替卡松)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=796d15449089, createdName=海豹, createdTime=Fri Apr 05 04:55:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]

相关资讯

Pediatr Allergy Immunol:舌下免疫治疗能够改变梯牧草过敏儿童的唾液lgA和全身免疫调控因子

舌下免疫治疗的免疫调控响应对过敏性儿童的全身和粘膜调控因子的影响仍旧大部分未知。最近,有研究人员在一个为期3年梯牧草花粉舌下免疫治疗的过敏性鼻炎儿童群体中,调查了相关的细胞因子和趋化因子水平以及lgA响应情况。研究发现,在3年的治疗后以及治疗结束2年后,GRAZAX®治疗的儿童表现出了显著更高的phl p1特异性唾液IgA和血清IgG4水平,以及显著更低的皮刺试验阳性率。另外,Th1相关的趋化因子

得了鼻炎会变笨?慢性鼻炎的规范治疗

鼻炎是一种高发且顽固的常见疾病。据统计,我国鼻炎发病率高达37%。即使如此,因为对鼻炎预防和治疗的重视不够,许多人经历了从无到有,急性拖成慢性的过程。随着生活品质的提高,大家的健康意识不断提升,鼻炎治疗得到了越来越多的关注。那么,慢性鼻炎到底应该如何治疗呢?

盘点:鼻炎进展盘点

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Clin Med:肖格伦综合征与慢性鼻窦炎患者的相关性分析 https://www.ncbi.nlm.nih.gov/pubmed/30704055最近,有研究人

盘点:鼻炎的机制进展

【1】J Leukoc Biol:过敏性鼻炎患者中,白介素-5能够诱导CD4+T细胞凋亡缺陷 https://www.ncbi.nlm.nih.gov/pubmed/30694585辅助性T细胞(Th)2极化在过敏性疾病的病理中具有重要的角色,而潜在的机制仍旧需要进一步的调查。类B细胞淋巴瘤蛋白-2蛋白12(Bcl2L12)具有抗凋亡的功能。最近,有研究人员阐释了过敏性鼻炎(AR)患者中,Bc

盘点:鼻炎与治疗进展

【1】Am J Rhinol Allergy:轻度到中度常年性变应性鼻炎儿童患者中鼻内纤维素粉治疗对哮喘的控制效果研究 常年性变应性鼻炎(PAR)常存在于哮喘患者中。据报道,鼻内纤维素粉(ICP)在改善PAR中是有效的。最近,有研究人员在患有过敏性哮喘(AA)的PAR儿童中,调查了是否ICP与鼻内糖皮质激素在改善哮喘控制和鼻症状方面效果的相当的。研究是一个单中心、随机、安慰剂-对照的

J Eval Clin Pract:过敏性鼻炎对成年人肠胃疾病影响研究

过敏性鼻炎(AR)与消化疾病之间的相关性已经有所报道;然而,这些研究只关注了AR患者中DDs的流行度情况。在特定DDs的个体中,AR对DD临床就诊频率的影响还未研究。更多的是,AR局部类固醇的使用与DDs的相关性也为调查。研究包括了16526名男性和18438名女性,年龄在21到30岁。该群体被分为AR组和非AR组,研究包括了8中常见的DDs。研究发现,在男性和女性中,所有常见的8中DDs与AR均